Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28720936 | 0.82 | ALDH1A1 (0.42) | CYP3A4GABRA1GABRB2ALDH1A1HPGD | |
| SCHEMBL465790 | 0.81 | CYP3A4 (0.47) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL7762531 | 0.81 | CYP3A4 (0.47) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL15092 | 0.80 | CYP3A4 (1.00) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL19891826 | 0.80 | CYP3A4 (0.47) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL9585196 | 0.80 | CYP3A4 (0.47) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL27946613 | 0.78 | CYP3A4 (0.95) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL19891828 | 0.75 | CYP3A4 (0.55) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL8964677 | 0.75 | CYP3A4 (0.54) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL93192 | 0.75 | CYP3A4 (0.79) | CYP3A4TRPA1GABRA1GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334236-B2 | Lactam-based compounds with a urethane or urea functional group, and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334236-B2 | Lactam-based compounds with a urethane or urea functional group, and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS LLC | 2012-06-14 | — | — | US | disclosed |
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS LLC | 2012-06-14 | — | — | US | disclosed |
| WO-2011022457-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | CUTA, PUF60, PAM | CYP3A4 2144/4885TRPA1 718/4885GABRA1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.